Arena Pharmaceuticals

Arena Pharmaceuticals completes phase Ib clinical trial

Friday, September 6, 2013 03:12 PM

Arena Pharmaceuticals has completed a phase Ib clinical trial for APD811, an investigational oral prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH). The company plans to initiate a phase II clinical trial for APD811 in the first quarter of 2014.

More... »

Quest Diagnostics

Arena initiates phase I trial of APD811 for hypertension

Friday, October 12, 2012 02:46 PM

Arena Pharmaceuticals, a San Diego-based biopharmaceutical company focused on novel drugs for weight management, cardiovascular disease, inflammation and other disorders, has initiated dosing in a phase I multiple dose clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin (IP) receptor for the treatment of pulmonary arterial hypertension (PAH).

More... »


FibroGen names VP, technical development

Monday, September 12, 2011 12:31 PM

FibroGen has named Michael Martinelli, Ph.D., vice president, technical development. In this role, Martinelli is responsible for the chemistry, manufacturing, and controls (CMC) development activities for FibroGen’s most advanced small molecule clinical candidates.

More... »

Arena posts phase I trial results

Wednesday, July 13, 2011 10:17 AM

Arena Pharmaceuticals has announced results from a phase I clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension, or PAH.

More... »


CWWeekly

April 20

Christie Clinic, PMG Research's 12th clinical research site, expands its geographic reach north to Illinois

Clinipace acquires Accovion to expand European presence, following an infusion of equity that could lead to more deals

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs